Clin2
NCT07231523Possibly a fitNot yet recruiting

Comparing two treatments for thymoma with myasthenia gravis

EfgartigimodIntravenous ImmunoglobulinMyasthenia Gravis Associated With Thymoma

Part of Brain & nervous system, Immune system & allergy clinical trials.

This trial tests whether a newer drug combination (EFG) works better than standard immunoglobulin (IVIG) for people who have both thymoma and myasthenia gravis and need surgery to remove the thymoma. The goal is to improve symptoms before and after the operation.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 3
Enrollment
64 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are between 18 and 75 years old
  • You have generalized myasthenia gravis (muscle weakness affecting more than just the eyes)
  • Your myasthenia gravis symptoms score (MG-ADL) is 6 or higher on a 0–24 scale
  • You have a type of thymoma (a tumor in the chest) shown on a CT or MRI scan
  • A team of doctors has confirmed you need surgery to remove the thymoma
  • You are in good overall health (American Society of Anesthesiologists grade 1 or 2) and have no major heart, lung, liver, kidney, or bleeding problems

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06587867Recruiting· Phase 3
Efgartigimod for seronegative myasthenia gravis

This study tests an experimental drug called efgartigimod (given through an IV) for people with a rare type of myasthenia gravis that doesn't show up on standard antibody tests. It aims to see if the drug can improve muscle weakness and daily function.

Toronto, Ontario
NCT06221501Not yet recruiting· Phase 2
Efgartigimod before and after thymoma surgery for myasthenia gravis

This trial tests giving a medication called efgartigimod before and after surgery for people who have both thymoma (a thymus tumor) and myasthenia gravis. The goal is to see if it helps improve muscle strength and recovery after tumor removal.

NCT07673744Recruiting· Phase 2
Maintenance treatment for myasthenia gravis after efgartigimod

This trial tests whether a follow-up treatment with ublituximab (given as an infusion) can help myasthenia gravis patients who first received efgartigimod. The goal is to see if it provides lasting control of MG symptoms.

Colorado Springs, Colorado
NCT06765161Recruiting· Phase 3
Efgartigimod for IVIG-dependent myasthenia gravis

This study tests a medication called efgartigimod for people with myasthenia gravis who need regular IVIG treatments. The goal is to see if efgartigimod can help reduce the need for IVIG.

Gatineau, Quebec
NCT06827587Not yet recruiting
Efgartigimod then Telitacicept for Myasthenia Gravis

This trial tests whether taking two drugs one after the other—efgartigimod followed by telitacicept—is safe and effective for people with generalized myasthenia gravis. It may offer a new treatment option if standard therapy isn't enough.

NCT06688253Not yet recruiting· Phase 4
Study of efgartigimod for myasthenia gravis crisis

This trial tests a drug called efgartigimod for people with myasthenia gravis who are experiencing a sudden, severe worsening of symptoms (crisis). The drug may help reduce the need for a breathing tube or speed up recovery.

Haifa

Hear when a new Myasthenia Gravis Associated With Thymoma trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.